Last reviewed · How we verify
concomitant therapy
Concomitant therapy refers to the simultaneous administration of two or more drugs to enhance therapeutic efficacy or manage multiple conditions.
At a glance
| Generic name | concomitant therapy |
|---|---|
| Sponsor | Ying HUANG |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Concomitant therapy is a treatment strategy rather than a single drug entity, involving the coordinated use of multiple pharmaceutical agents. The mechanism depends entirely on the specific drugs being combined; synergistic effects may occur when drugs target complementary pathways or when one agent enhances the bioavailability or efficacy of another.
Approved indications
Common side effects
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma (PHASE1)
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Use of Augmented Reality Glasses and Noise-Cancelling Headphones to Reduce Dental Anxiety in Adult Patients (NA)
- Prevent TB: Choice Architecture for TPT Delivery (NA)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- concomitant therapy CI brief — competitive landscape report
- concomitant therapy updates RSS · CI watch RSS
- Ying HUANG portfolio CI